急性呼吸促拍症候群治療薬市場:パイプラインレビュー(2020年上半期)

◆英語タイトル:Acute Respiratory Distress Syndrome - Pipeline Review, H1 2020
◆商品コード:GDATA20MY0763
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2020年1月31日
◆ページ数:129
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,000 ⇒換算¥210,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD4,000 ⇒換算¥420,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD6,000 ⇒換算¥630,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Acute Respiratory Distress Syndrome – Pipeline Review, H1 2020
Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Acute Respiratory Distress Syndrome – Pipeline Review, H1 2020, provides an overview of the Acute Respiratory Distress Syndrome (Respiratory) pipeline landscape.

Acute respiratory distress syndrome (ARDS) occurs when fluid fills up the air sacs in lungs. This leads to low oxygen levels in the blood. Common causes of ARDS include sepsis, inhalation of harmful substances, severe pneumonia and head or chest injury. Signs and symptoms of ARDS include severe shortness of breath, labored and unusually rapid breathing, low blood pressure and confusion and extreme tiredness.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Acute Respiratory Distress Syndrome – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Acute Respiratory Distress Syndrome (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Acute Respiratory Distress Syndrome (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Acute Respiratory Distress Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 6, 6, 15 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Acute Respiratory Distress Syndrome (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Acute Respiratory Distress Syndrome (Respiratory).
- The pipeline guide reviews pipeline therapeutics for Acute Respiratory Distress Syndrome (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Acute Respiratory Distress Syndrome (Respiratory) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Acute Respiratory Distress Syndrome (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Acute Respiratory Distress Syndrome (Respiratory)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Acute Respiratory Distress Syndrome (Respiratory).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Acute Respiratory Distress Syndrome (Respiratory) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

【レポートの目次】

Table of Contents
Introduction
Acute Respiratory Distress Syndrome – Overview
Acute Respiratory Distress Syndrome – Therapeutics Development
Acute Respiratory Distress Syndrome – Therapeutics Assessment
Acute Respiratory Distress Syndrome – Companies Involved in Therapeutics Development
Acute Respiratory Distress Syndrome – Drug Profiles
Acute Respiratory Distress Syndrome – Dormant Projects
Acute Respiratory Distress Syndrome – Discontinued Products
Acute Respiratory Distress Syndrome – Product Development Milestones
Appendix

List of Tables
Number of Products under Development for Acute Respiratory Distress Syndrome, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Acute Respiratory Distress Syndrome - Pipeline by A6 Pharmaceuticals LLC, H1 2020
Acute Respiratory Distress Syndrome - Pipeline by Aqualung Therapeutics Corp, H1 2020
Acute Respiratory Distress Syndrome - Pipeline by Athersys Inc, H1 2020
Acute Respiratory Distress Syndrome - Pipeline by Bayer AG, H1 2020
Acute Respiratory Distress Syndrome - Pipeline by Cells for Cells SA, H1 2020
Acute Respiratory Distress Syndrome - Pipeline by Commence Bio Inc, H1 2020
Acute Respiratory Distress Syndrome - Pipeline by Cynata Therapeutics Ltd, H1 2020
Acute Respiratory Distress Syndrome - Pipeline by Emergent BioSolutions Inc, H1 2020
Acute Respiratory Distress Syndrome - Pipeline by Eunoia Biotech LLC, H1 2020
Acute Respiratory Distress Syndrome - Pipeline by Exvastat Ltd, H1 2020
Acute Respiratory Distress Syndrome - Pipeline by Faron Pharmaceuticals Oy, H1 2020
Acute Respiratory Distress Syndrome - Pipeline by Histocell SL, H1 2020
Acute Respiratory Distress Syndrome - Pipeline by Hydra Biosciences Inc, H1 2020
Acute Respiratory Distress Syndrome - Pipeline by Implicit Bioscience Ltd, H1 2020
Acute Respiratory Distress Syndrome - Pipeline by In2cure AB, H1 2020
Acute Respiratory Distress Syndrome - Pipeline by IsletOne AB, H1 2020
Acute Respiratory Distress Syndrome - Pipeline by Liminal BioSciences Inc, H1 2020
Acute Respiratory Distress Syndrome - Pipeline by LTT Bio-Pharma Co Ltd, H1 2020
Acute Respiratory Distress Syndrome - Pipeline by Meridigen Biotech Co Ltd, H1 2020
Acute Respiratory Distress Syndrome - Pipeline by Nano Biotherapeutics Inc, H1 2020
Acute Respiratory Distress Syndrome - Pipeline by Northern Therapeutics Inc, H1 2020
Acute Respiratory Distress Syndrome - Pipeline by Orbsen Therapeutics Ltd, H1 2020
Acute Respiratory Distress Syndrome - Pipeline by Restore Therapeutics LLC, H1 2020
Acute Respiratory Distress Syndrome - Pipeline by Savara Inc, H1 2020
Acute Respiratory Distress Syndrome - Pipeline by SolAeroMed Inc, H1 2020
Acute Respiratory Distress Syndrome - Pipeline by Vasomune Inc, H1 2020
Acute Respiratory Distress Syndrome - Pipeline by Windtree Therapeutics Inc, H1 2020
Acute Respiratory Distress Syndrome - Dormant Projects, H1 2020
Acute Respiratory Distress Syndrome - Dormant Projects, H1 2020 (Contd..1), H1 2020
Acute Respiratory Distress Syndrome - Discontinued Products, H1 2020

【掲載企業】

A6 Pharmaceuticals LLC
Aqualung Therapeutics Corp
Athersys Inc
Bayer AG
Cells for Cells SA
Commence Bio Inc
Cynata Therapeutics Ltd
Emergent BioSolutions Inc
Eunoia Biotech LLC
Exvastat Ltd
Faron Pharmaceuticals Oy
Histocell SL
Hydra Biosciences Inc
Implicit Bioscience Ltd
In2cure AB
IsletOne AB
Liminal BioSciences Inc
LTT Bio-Pharma Co Ltd
Meridigen Biotech Co Ltd
Nano Biotherapeutics Inc
Northern Therapeutics Inc
Orbsen Therapeutics Ltd
Restore Therapeutics LLC
Savara Inc
SolAeroMed Inc
Vasomune Inc
Windtree Therapeutics Inc

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[急性呼吸促拍症候群治療薬市場:パイプラインレビュー(2020年上半期)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆